Frailty as a predictor of mortality and readmission rate in secondary mitral regurgitation.

Robert Uzel, Richard Rezar, Raphael Romano Bruno, Sarah Wernly, Christian Jung, Georg Delle Karth, Christian Datz, Friedrich Hoppichler, Bernhard Wernly

Journal: Wiener klinische Wochenschrift 2023;135(23-24):696-702

PMID: 36633679

Abstract

INTRODUCTION

Selection in patients with functional mitral regurgitation (MR) to identify responders to interventions is challenging. In these patients, frailty might be used as a multidimensional parameter to summarize the resilience to stressors. Our objective was to evaluate frailty as a predictor of outcome in patients with moderate to severe secondary MR.

METHODS

We conducted a single-center retrospective observational cohort study and included 239 patients with moderate to severe secondary MR aged 65 years or older between 2014 and 2020. Echocardiography was performed at baseline; frailty was evaluated using the clinical frailty scale (CFS). The combined primary endpoint was hospitalization for heart failure and all-cause mortality.

RESULTS

A total of 53% (127) of all patients were classified as CFS 4 (living with mild frailty) or higher. Frail patients had a higher risk for the combined endpoint (hazard ratio, HR 3.70, 95% confidence interval, CI 2.12-6.47; p < 0.001), 1‑year mortality (HR 5.94, 95% CI 1.76-20.08; p < 0.001) even after adjustment for EuroSCORE2. The CFS was predictive for the combined endpoint (AUC 0.69, 95% CI 0.62-0.75) and outperformed EuroSCORE2 (AUC 0.54, 95% CI 0.46-0.62; p = 0.01). In sensitivity analyses, we found that frailty was associated with adverse outcomes at least in trend in all subgroups.

CONCLUSION

For older, medically treated patients with moderate to severe secondary mitral regurgitation, frailty is an independent predictor for the occurrence of death and heart failure-related readmission within 1 year and outperformed the EuroSCORE2. Frailty should be assessed routinely in patients with heart failure to guide clinical decision making for mitral valve interventions or conservative treatment.

© 2023. The Author(s).

Address: Department of Internal Medicine, Saint John of God Hospital, Teaching Hospital of the Paracelsus Medical Private University, Kajetanerplatz 1, 5020, Salzburg, Austria. [email protected].; Department of Cardiology, Klinik Floridsdorf, Brünner Str. 68, 1210, Vienna, Austria. [email protected].; Department of Cardiology and Intensive Care Medicine, Paracelsus Medical University of Salzburg, Müllner Hauptstr. 48, 5020, Salzburg, Austria.; Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.; Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical Private University, Paracelsusstr. 37, 5110, Oberndorf, Austria.; Department of Cardiology, Klinik Floridsdorf, Brünner Str. 68, 1210, Vienna, Austria.; Department of Internal Medicine, Saint John of God Hospital, Teaching Hospital of the Paracelsus Medical Private University, Kajetanerplatz 1, 5020, Salzburg, Austria.; Special Institute for Preventive Cardiology and Nutrition, SIPCAN-Initiative für ein gesundes Leben, Salzburg, Austria.; Institute of general practice, family medicine and preventive medicine, Paracelsus Medical University, Strubergasse 21, 5020, Salzburg, Austria.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.